Payment overview · 2025
General Payments
$1,036.69
67 reported records · 16 companies
Healthcare provider profile · identity verified
Samuel G. Poser, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · COLUMBUS, WI · NPI 1346243821
Verified facts
What the public records show
CMS Open Payments records show Samuel G. Poser, M.D. received $1,036.69 in general payments during 2025 across 67 reported records.
Novo Nordisk Inc accounted for 15.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Synthroid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Zenpep by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $161.80 | 15.6% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $155.58 | 15.0% | 13 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $154.90 | 14.9% | 14 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $91.31 | 8.8% | 5 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $81.76 | 7.9% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $60.26 | 5.8% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $48.14 | 4.6% | 3 | 2025 |
| BridgeBio Pharma, Inc. | Unresolved — no canonical attribution shown | $45.72 | 4.4% | 3 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$44.00 | 4.2% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $39.15 | 3.8% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $35.87 | 3.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $32.19 | 3.1% | 2 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $28.92 | 2.8% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $21.82 | 2.1% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $21.71 | 2.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.56 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,036.69 | 67 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $123.07 | 10 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $116.14 | 9 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $96.87 | 10 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $91.31 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $84.27 | 5 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $81.76 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $67.30 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $60.26 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $56.91 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $53.22 | 4 | 2025 |
Source payment records
|
|||||
| Attruby Normalized: attruby |
Drug | BridgeBio Pharma, Inc. | $45.72 | 3 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $44.00 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $39.15 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $38.34 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $35.87 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $33.27 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $32.19 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $32.19 | 2 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc. | $28.92 | 2 | 2025 |
Source payment records
|
|||||
| THORATEC HEARTMATE 3 LVAS IMPLANT KIT Normalized: thoratec heartmate 3 lvas implant kit |
Device | Abbott Laboratories | $21.82 | 1 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $21.71 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $20.27 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.90 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.90 | 2 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $15.46 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $15.14 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.69 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 84 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 58 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
84 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
84 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 387 | 88 |
| Amlodipine Besylate | Amlodipine Besylate | 282 | 74 |
| Metoprolol Tartrate | Metoprolol Tartrate | 221 | 54 |
| Lisinopril | Lisinopril | 215 | 58 |
| Potassium Chloride | Potassium Chloride | 213 | 49 |
| Furosemide | Furosemide | 206 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 205 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 204 | 63 |
| Levothyroxine Sodium | Levothyroxine Sodium | 203 | 49 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 166 | 25 |
| Gabapentin | Gabapentin | 160 | 38 |
| Bumetanide | Bumetanide | 155 | 36 |
| Losartan Potassium | Losartan Potassium | 155 | 37 |
| Simvastatin | Simvastatin | 139 | 33 |
| Lorazepam | Lorazepam | 137 | 30 |
| Azithromycin | Azithromycin | 129 | 102 |
| Hydrochlorothiazide | Hydrochlorothiazide | 129 | 35 |
| Omeprazole | Omeprazole | 119 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 119 | 33 |
| Sertraline Hcl | Sertraline Hcl | 112 | 17 |
| Tramadol Hcl | Tramadol Hcl | 112 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 107 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 102 | 13 |
| Metformin Hcl | Metformin Hcl | 94 | 23 |
| Eliquis | Apixaban | 84 | 19 |
| Xarelto | Rivaroxaban | 78 | 18 |
| Warfarin Sodium | Warfarin Sodium | 77 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 72 | 21 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 68 | 48 |
| Trazodone Hcl | Trazodone Hcl | 68 | 15 |
| Allopurinol | Allopurinol | 66 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 66 | 16 |
| Metformin Hcl Er | Metformin Hcl | 66 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 65 | 47 |
| Ozempic | Semaglutide | 58 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 54 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 54 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 53 | 45 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 52 | 52 |
| Montelukast Sodium | Montelukast Sodium | 52 | 14 |
| Alprazolam | Alprazolam | 51 | suppressed |
| Carvedilol | Carvedilol | 51 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 51 | 15 |
| Prednisone | Prednisone | 50 | 23 |
| Pregabalin | Pregabalin | 49 | suppressed |
| Spironolactone | Spironolactone | 48 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 46 | 20 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 46 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 44 | 28 |
| Latanoprost | Latanoprost | 43 | suppressed |
| Famotidine | Famotidine | 42 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 40 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 37 | suppressed |
| Glipizide | Glipizide | 36 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 33 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 29 |
| Hydralazine Hcl | Hydralazine Hcl | 32 | suppressed |
| Cephalexin | Cephalexin | 31 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 31 | 16 |
| Oxycontin | Oxycodone Hcl | 30 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Digoxin | Digoxin | 29 | suppressed |
| Irbesartan | Irbesartan | 29 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 29 | suppressed |
| Sucralfate | Sucralfate | 29 | 11 |
| Finasteride | Finasteride | 28 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Fentanyl | Fentanyl | 27 | suppressed |
| Glipizide Er | Glipizide | 26 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 26 | suppressed |
| Ezetimibe | Ezetimibe | 25 | suppressed |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 25 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 25 | suppressed |
| Colchicine | Colchicine | 24 | suppressed |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 17 |
| Clotrimazole | Clotrimazole | 23 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Nystatin | Nystatin | 22 | 11 |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Fluconazole | Fluconazole | 21 | 13 |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 19 | suppressed |
| Clonazepam | Clonazepam | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Ursodiol | Ursodiol | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | 12 |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Timolol Maleate | Timolol Maleate | 16 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Nystop | Nystatin | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Jardiance | Empagliflozin | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Meloxicam | Meloxicam | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,036.69 · 67 records | Novo Nordisk Inc | ABRYSVO, Attruby, CAMZYOS, COMIRNATY, CREON, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, GEMTESA, JARDIANCE, LEQEMBI, LINZESS, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, SAPIEN 3 Ultra RESILIA, THORATEC HEARTMATE 3 LVAS IMPLANT KIT, UBRELVY, VALTOCO, VRAYLAR, Wegovy, ZAVZPRET, ZENPEP, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error